Sujal Shah
2020
In 2020, Sujal Shah earned a total compensation of $2.6M as Chief Executive Officer at Cymabay Therapeutics, a 3% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $306,000 |
|---|---|
| Option Awards | $1,823,562 |
| Salary | $510,000 |
| Other | $4,573 |
| Total | $2,644,135 |
Shah received $1.8M in option awards, accounting for 69% of the total pay in 2020.
Shah also received $306K in non-equity incentive plan, $510K in salary and $4.6K in other compensation.
Rankings
In 2020, Sujal Shah's compensation ranked 4,338th out of 13,090 executives tracked by ExecPay. In other words, Shah earned more than 66.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,338 out of 13,090 | 67th |
Division Manufacturing | 1,760 out of 5,624 | 69th |
Major group Chemicals And Allied Products | 688 out of 2,257 | 70th |
Industry group Drugs | 589 out of 1,957 | 70th |
Industry Pharmaceutical Preparations | 449 out of 1,462 | 69th |
Source: SEC filing on April 26, 2022.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019